Search results for "agora"

showing 10 items of 64 documents

The problem of misidentification between edible and poisonous wild plants: Reports from the Mediterranean area

2018

Abstract Today, in many European countries, people are looking for wild edible plants to experience new tastes and flavors, by following the new trend of being green and environmentally friendly. Young borage and spinach leaves can be easily confused by inexpert pickers with those of other plants, including poisonous ones, such as Mandragora autumnalis Bertol. (mandrake) or Digitalis purpurea L. (foxglove), common in southern and northern Italy respectively. In the last twenty years, several cases of intoxication by accidental ingestion of mandrake and foxglove have been reported. The purpose of this work was to perform a pharmacognostic characterization of young leaves from borage, mandrak…

0106 biological sciences0301 basic medicineChromatography GasDigitalis GlycosidePhytochemicalsIntoxicationBiologyPhytochemicalToxicology010603 evolutionary biology01 natural sciencesEdible plantGas Chromatography-Mass SpectrometryAccidental ingestion03 medical and health sciencesPlant leaveAlkaloidsAlkaloidHumansDiscriminant analysePoisonous plants Edible plants Plant leaves Accidental ingestion Intoxication Discriminant analysesBorageTraditional medicineMediterranean RegionSettore BIO/02 - Botanica SistematicaDigitalis purpureafood and beveragesMandragora autumnalisDigitalis GlycosidesDiscriminant analysesGeneral MedicineMandrakebiology.organism_classificationPoisonous plantPlant LeavesPlants Toxic030104 developmental biologyPhytochemicalItalyChromatography GaPoisonous plantsSettore BIO/03 - Botanica Ambientale E ApplicataAccidental ingestionEdible plantsEdible plantsMediterranean areaPlants EdibleFood ScienceHuman
researchProduct

GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathw…

2017

Contains fulltext : 177350.pdf (Publisher’s version ) (Closed access) The molecular genetics of panic disorder (PD) with and without agoraphobia (AG) are still largely unknown and progress is hampered by small sample sizes. We therefore performed a genome-wide association study with a dimensional, PD/AG-related anxiety phenotype based on the Agoraphobia Cognition Questionnaire (ACQ) in a sample of 1370 healthy German volunteers of the CRC TRR58 MEGA study wave 1. A genome-wide significant association was found between ACQ and single non-coding nucleotide variants of the GLRB gene (rs78726293, P=3.3 x 10-8; rs191260602, P=3.9 x 10-8). We followed up on this finding in a larger dimensional AC…

0301 basic medicineMaleStartle responseReflex StartleQH301 BiologyGenome-wide association studyGene mutationAnxiety0302 clinical medicineCognitionReceptors GlycineGene FrequencyGermanyGWASHyperekplexiaGeneticsPanic disordermedicine.diagnostic_testStartleBrainFearGLRBAnxiety DisordersPsychiatry and Mental healthSchizophreniaUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Panic DisorderFemalemedicine.symptomPsychologyBDCRC0321 Neuroscience. Biological psychiatry. NeuropsychiatryClinical psychologyAdultGenotypeNDASQH426 Genetics03 medical and health sciencesCellular and Molecular NeuroscienceQH301Fear networkSpastic mousemedicineHumansGenetic Predisposition to DiseaseMolecular BiologyQH426AgoraphobiaAllelesNeurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7]Panic disorderOther Research Radboud Institute for Health Sciences [Radboudumc 0]medicine.diseaseStartle reaction030104 developmental biologyMCPCase-Control StudiesMutationRC0321030217 neurology & neurosurgeryAgoraphobiaGenome-Wide Association StudyMolecular psychiatry
researchProduct

Enhancing in vivo exposure in the treatment of panic disorder and agoraphobia using location-based technologies: a case study

2019

Panic disorder (PD) is quite prevalent and often appears along with agoraphobia (PD/A). The treatment of choice is cognitive behavioral therapy (CBT). Transdiagnostic intervention, an emotion-focused, cognitive behavioral intervention that has led to the Unified Protocol (UP), emphasizes the common underlying mechanisms that contribute to the development and maintenance of emotional disorders such as PD/A. A core feature of this treatment approach is in vivo exposure (IVE) to feared situations, which aims to prevent avoidance behaviors and encourages the patient to confront feared situations gradually. It is a difficult component for patients, especially when implementing the exposure on t…

050103 clinical psychologybusiness.industrymedicine.medical_treatmentPanic disorder05 social sciencesmedicine.disease030227 psychiatryCognitive behavioral therapyTrastorns de pànic03 medical and health sciencesPsychiatry and Mental healthClinical Psychology0302 clinical medicineTecnologiaIntervention (counseling)medicine0501 psychology and cognitive sciencesbusinessClinical psychologyAgoraphobia
researchProduct

Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo

1994

Summary Side effects play a significant role in the selection of drugs to be used in panic disorder/agoraphobia whose polyphobic symptomatology often includes a suspiciousness about taking drugs and a fear of undesired side effects which may lead to the refusal of treatment. The safety, side effects and patients' acceptance of alprazolam and imipramine versus placebo were evaluated in 1168 subjects with panic disorder/agoraphobia who had been enrolled in the second phase of the Upjohn World Wide Panic Study. Side effects that worsened over baseline to a greater extent with alprazolam than with imipramine and placebo were sedation, fatigue/weakness, memory problems, ataxia and slurred speech…

AdultImipramineAdolescentSide effectPoison controlPlaceboImipramineDouble-Blind MethodmedicineHumansPharmacology (medical)Biological PsychiatryAgedPsychiatric Status Rating ScalesPharmacologyAlprazolambusiness.industryPanic disorderPanicMiddle Agedmedicine.diseasePsychiatry and Mental healthNeurologyAlprazolamAnesthesiaPanic DisorderPatient ComplianceNeurology (clinical)medicine.symptombusinessAgoraphobiamedicine.drugEuropean Neuropsychopharmacology
researchProduct

Predictors of the application of exposure in vivo in the treatment of agoraphobia in an outpatient clinic: An exploratory approach.

2015

AbstractObjective: Although exposure in vivo is considered to be the most effective therapy component in the treatment of agoraphobia (AG), there is a remarkable lack of its application in psychotherapeutic routine care. We examined the severity of anxiety, psychological distress/comorbidity, therapeutic process/alliance, and sociodemographic status as potential predictors of in vivo exposure. Method: We applied correlational analyses and logistic regression analyses in a sample of N = 92 patients (main diagnosis AG) in an outpatient setting. Results: Logistic regression analyses did not yield any significant single predictors, whereas a combination of a subset of predictors significantly p…

AdultMale050103 clinical psychologyPsychotherapistPsychotherapeutic ProcessesImplosive TherapyLogistic regressionAmbulatory Care Facilities03 medical and health sciences0302 clinical medicineIn vivoMedicineOutpatient clinicHumans0501 psychology and cognitive sciencesRoutine careAgoraphobiabusiness.industryPanic disorder05 social sciencesProfessional-Patient Relationsmedicine.diseaseComorbidity030227 psychiatryClinical PsychologyOutcome and Process Assessment Health CareAnxietyPanic DisorderFemalemedicine.symptombusinessAgoraphobiaPsychotherapy research : journal of the Society for Psychotherapy Research
researchProduct

Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine.

1998

A six-week double-blind placebo-controlled trial of fluvoxamine was undertaken in 46 patients suffering from panic disorder with or without agoraphobia diagnosed by DSM-III-R guidelines. Average daily dosage of fluvoxamine was 160 mg, with a highest permitted dose of 300 mg/day. Weekly evaluation included a diary in which the number, severity, and duration of full-blown and limited panic attacks and the duration and severity of anticipating fear, CAS, GAS, CGI, HAM-D, adverse effects and the number of capsules not taken were noted. Fluvoxamine was not significantly superior to placebo with regard to the main outcome criterion, i.e., the reduction in the number of panic attacks, but it was s…

AdultMaleAdolescentFluvoxaminePlacebolaw.inventionRandomized controlled trialDouble-Blind Methodlawmental disordersmedicineHumansPharmacology (medical)Adverse effectAgedPsychiatric Status Rating ScalesPanic disorderPanicGeneral MedicineMiddle Agedmedicine.diseasehumanitiesPsychiatry and Mental healthAnti-Anxiety AgentsFluvoxamineAnesthesiaPanic DisorderFemalemedicine.symptomDrug MonitoringPsychologyAnxiety disorderSelective Serotonin Reuptake Inhibitorsmedicine.drugAgoraphobiaPharmacopsychiatry
researchProduct

MicroRNA hsa-miR-4717-5p regulates RGS2 and may be a risk factor for anxiety-related traits

2015

Regulator of G-protein Signaling 2 (RGS2) is a key regulator of G-protein-coupled signaling pathways involved in fear and anxiety. Data from rodent models and genetic analysis of anxiety-related traits and disorders in humans suggest down-regulation of RGS2 expression to be a risk factor for anxiety. Here we investigated, whether genetic variation in microRNAs mediating posttranscriptional down-regulation of RGS2 may be a risk factor for anxiety as well. 75 microRNAs predicted to regulate RGS2 were identified by four bioinformatic algorithms and validated experimentally by luciferase reporter gene assays. Specificity was confirmed for six microRNAs (hsa-miR-1271-5p, hsa-miR-22-3p, hsa-miR-3…

AdultMaleCandidate geneSingle-nucleotide polymorphismMIR4717ComorbidityBiologyBioinformaticsPolymorphism Single NucleotideCellular and Molecular NeuroscienceGenes ReporterRisk FactorsmedicineHumansIKBKEGenetic Predisposition to DiseaseAllelepanic disorderLuciferases3' Untranslated RegionsAgoraphobiaAllelesGenetic Association StudiesGenetics (clinical)miRNAGeneticsPanic disorderassociationComputational BiologyReproducibility of Resultsmedicine.diseaseAnxiety DisordersMicroRNAsPsychiatry and Mental healthGene Expression RegulationCase-Control StudiesLinear ModelsAnxiety sensitivityAnxietyFemalemedicine.symptomgene regulationRGS ProteinsAgoraphobiaAmerican Journal of Medical Genetics Part B-neuropsychiatric Genetics
researchProduct

Using Augmented Reality to Treat Phobias

2005

Virtual reality (VR) is useful for treating several psychological problems, including phobias such as fear of flying, agoraphobia, claustrophobia, and phobia to insects and small animals. We believe that augmented reality (AR) could also be used to treat some psychological disorders. AR and VR share some advantages over traditional treatments. However, AR gives a greater feeling of presence (the sensation of being there) and reality judgment (judging an experience as real) than VR because the environment and the elements the patient uses to interact with the application are real. Moreover, in AR users see their own hands, feet, and so on, whereas VR only simulates this experience. With thes…

AdultMaleComputer sciencemedia_common.quotation_subjectCockroachesVirtual realitycomputer.software_genreFear of flyingUser-Computer InterfaceSensationComputer GraphicsmedicineAnimalsHumansComputer Simulationmedia_commonPhobiasMultimediaSpidersModels Theoreticalmedicine.diseaseComputer Graphics and Computer-Aided DesignTreatment OutcomeMultimediaPhobic DisordersFeelingTherapy Computer-AssistedClaustrophobiaFemaleAugmented realityDesensitization PsychologiccomputerSoftwareCognitive psychologyAgoraphobiaIEEE Computer Graphics and Applications
researchProduct

Blood endocannabinoid levels in patients with panic disorder.

2020

Abstract Background The development and maintenance of anxiety disorders is not fully understood. There is consensus in the literature that in addition to genetic factors, social, psychological and neurobiological factors are of crucial importance. The present exploratory study investigates the influence of the endocannabinoids (EC) and related N-acylethanolamines (NA) on the maintenance of panic disorder (PD). Methods A total of n = 36 PD and n = 26 healthy controls (HC) were included in the study. Baseline characteristics showed no differences between the two groups. The participants were exposed to the Trier Social Stress Test (TSST) for reliable laboratory stress induction. Blood sample…

AdultMaleHypothalamo-Hypophyseal SystemHydrocortisoneEndocrinology Diabetes and MetabolismPhysiologyPituitary-Adrenal System03 medical and health sciences0302 clinical medicineEndocrinologyHeart RateTrier social stress testMedicineHumansSalivaBiological PsychiatryEndocrine and Autonomic Systemsbusiness.industryPanic disorderStressorRepeated measures designMiddle Agedmedicine.diseaseEndocannabinoid system030227 psychiatryPsychiatry and Mental healthEthanolaminesAnxietyPanic DisorderFemalemedicine.symptombusinessPsychosocial030217 neurology & neurosurgeryStress PsychologicalAgoraphobiaEndocannabinoidsPsychoneuroendocrinology
researchProduct

Drug treatment of panic disorder: early response to treatment as a predictor of final outcome

1990

One of the core problems in clinical research is the detection of early changes in target symptoms that predict future therapeutic outcome. To analyze potential predictors of outcome, data of a multicenter study on patients with panic disorder were used. A total of 1010 patients were randomly allocated either to alprazolam, imipramine or placebo treatment. Early improvement in the number of spontaneous panic attacks within the first week of treatment predicted outcome exclusively in the alprazolam group. In contrast, placebo responders and nonresponders were differentiated by early changes in anticipatory anxiety intensity. For tricyclic antidepressants such as imipramine an evaluation peri…

AdultMaleImipraminemedicine.medical_specialtyPlaceboImipramineDouble-Blind MethodInternal medicinemedicineHumansPsychiatryAgoraphobiaPsychiatric Status Rating Scaleschemistry.chemical_classificationAlprazolamPanic disorderPanicmedicine.diseaseAnxiety DisordersPanicPsychiatry and Mental healthClinical researchchemistryAlprazolamAnxietyFemalemedicine.symptomArousalPsychologyTricyclicmedicine.drugActa Psychiatrica Scandinavica
researchProduct